The prognostic value of PET/CT in clinical stage I lung cancer patients: A propensity-match analysis.

Abstract Introduction The application of PET/CT directly improved treatment choice and management in 25% of non-small cell lung cancer patients and 29% of small cell lung cancer patients. However, the long-term outcome of altering the management of these patients remains unclear. The aim of this study was to compare the 5-year overall survival rates of two groups of clinical stage I lung cancer patients: those who received PET/CT and those who did not.Methods Data were obtained from the Taiwan Society of Cancer Registry. There were 6,587 clinical stage I lung cancer patients analyzed between 2009 and 2014 in this retrospective study. We performed propensity matching to reduce the bias; it resulted in both groups having 2,649 patients. We measured the 1, 3, and 5-year survival rates of all clinical stage I lung cancer patients and the survival rates of pathological I, II and III lung cancer patients and compared the survival rates between clinical stage I lung cancer patients with PET/CT scans and patients without PET/CT scans.Results The 1, 3, and 5-year survival rates of all clinical stage I lung cancer patients are 97.2%, 88.2% and 79.0%, respectively. The 1, 3, and 5-year survival rates are 97.0%, 88.2% and 79.8% in the PET/CT group and 97.5%, 88.1% and 78.2% in the no PET/CT group; there was no statistical difference (p= 0.6528).Conclusion Although stage I lung cancer patients who received PET/CT had their management strategies modified and avoided any unnecessary thoracotomies, our data showed that there was no 5-year survival benefit for these patients.

Download Full-text

Relationship between primary lesion FDG uptake and clinical stage at PET–CT for non-small cell lung cancer patients: An observation

Lung Cancer ◽

10.1016/j.lungcan.2009.07.009 ◽

2010 ◽

Vol 68 (3) ◽

pp. 394-397 ◽

Cited By ~ 17

Author(s):

Minghuan Li ◽

Yun Sun ◽

Yuhui Liu ◽

Anqin Han ◽

Shuqiang Zhao ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Clinical Stage ◽

Small Cell ◽

Primary Lesion ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

Pet Ct

Download Full-text

Trends in pneumonectomy for treatment of small-cell lung cancer

Asian Cardiovascular and Thoracic Annals ◽

10.1177/0218492320955054 ◽

2020 ◽

Vol 28 (9) ◽

pp. 583-591

Author(s):

Jasmine Zhao ◽

Alexandra Nguyen ◽

Li Ding ◽

Elizabeth A David ◽

Scott M Atay ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Clinical Stage ◽

Small Cell ◽

Stage I ◽

Small Cell Lung ◽

Lung Cancer Patients

Background According to practice guidelines, patients with clinical stage T1–2 node-negative small-cell lung cancer are candidates for surgical resection. However, the role of pneumonectomy in small-cell lung cancer patients is not well understood. The objective of this study was to assess the extent to which pneumonectomy is used and to evaluate the survival implications for small-cell lung cancer patients who underwent pneumonectomy. Methods A total of 106 small-cell lung cancer patients who underwent pneumonectomy between 2006 and 2016 and met the study criteria were identified in the National Cancer Database. Demographics and treatment regimens are described, and overall survival was assessed using Kaplan-Meier and log-rank tests. Results The most common treatment was surgery with adjuvant chemotherapy, followed by surgery only and surgery with neoadjuvant therapy. The 5-year overall survival for the entire cohort after pneumonectomy was 23%. In subgroup analysis, the 5-year overall survival was 30% for guideline-concordant clinical stage I patients and 28% for clinical stage II/III patients who underwent pneumonectomy. There was no statistical difference in survival according to pathologic N disease. Patients with a right-sided pneumonectomy had higher mortality than patients with a left-sided pneumonectomy. Conclusions This study suggests a role for pneumonectomy in clinical stage I and potentially some clinical stage II and III small-cell lung cancer patients. Right-sided pneumonectomy is associated with higher mortality and should be approached with caution. Despite declining trends over the past decades, pneumonectomy is still an effective treatment that is able to achieve acceptable survival outcomes.

Download Full-text